Media Center Found (709)
Array ( [cache_time] => 0 [counts_time] => 0.0058479309082031 [query_time] => 0.0041549205780029 [total_time] => 0.010002851486206 )
April 6, 2008

The company raised the finance from Docor International, Moshe (Mori) Arkin and a number of undisclosed institutional investors.

 

More
March 23, 2008

Nava Swersky Sofer congratulating Israel on it's 60th anniversary on a special Forbes edition. 

More
March 22, 2008

The unique case-controlled DNA database for genetic association studies will allow the scientific community to access DNA samples directly via the Internet (www.hugr.org) and test genes of interest.

More
March 13, 2008

The conference was held in Jerusalem, on March 13, 2008, under the auspices of The Louis Frieberg Center for East Asian Studies, titled: "Water Management in China: Mitigation of Challenges and Prospects for Sino-Israeli Cooperation"

More
March 11, 2008

The Hebrew University Genetic Resource (HUGR) platform includes 15,000 DNA samples of Ashkenazi Jews

More
March 11, 2008

The Hebrew University Genetic Resource (HUGR) platform includes 15,000 DNA samples of Ashkenazi Jews

More
February 28, 2008

Scientists from the School of Pharmacy at the Hebrew University of Jerusalem discovered a novel orally available drug that prevents metastasis formation in various types of cancers. 

More
February 27, 2008

cientists from the School of Pharmacy at the Hebrew University of Jerusalem discovered a novel orally available drug that prevents metastasis formation in various types of cancers.

More
February 13, 2008

Yissum spin-off Morria Biopharmaceuticals,  a biopharmaceutical company focused on the development of novel anti- inflammatory drugs, announced the preliminary safety results from its Phase I safety and tolerability study of MRX-4 in 16 patients...

More
February 12, 2008

Yissum spin-off Morria Biopharmaceuticals, a biopharmaceutical company focused on the development of novel anti- inflammatory drugs, announced the preliminary safety results from its Phase I safety and tolerability study of MRX-4 in 16 patients...

More
January 28, 2008

Globes article portraying Israeli Technology Transfer (Hebrew)

More
January 22, 2008

Israel 21c portraying Nava Swersky Sofer, Yissum's President & CEO 

More
January 22, 2008

The Acetylcholinesterase (AChE) Program is being conducted

under the agreement the Company entered into with Yissum Research and

Development Company, the technology transfer arm of the Hebrew University of

Jerusalem, Israel, and the Boyce...

More
January 13, 2008

The FDA approved the trial at 5 Israeli hospitals and one in Arizona. 

 

More
January 9, 2008

Yissum and Eucalyptus Biosciences Sign Licensing Agreement for the Development of a Small Molecule for the Treatment of Neurodegenerative Diseases

More
December 28, 2007

Israel's Universities and institutes are all about developing and selling technology 

More
December 25, 2007

Yissum and BioLineRx signed a worldwide exclusive license agreement for the development and commercialization of BL-4060, a small molecule drug candidate for the treatment of cancer.

More
December 25, 2007

Yissum announced the formation of Nanolymf, a biotechnology start up company dedicated to advancing a nanotechnology controlled release drug delivery platform that increases the bioavailability of orally administrated lipophilic drugs.

More
December 20, 2007

Jerusalem-based Yissum has formed a spin-off company - Nanolymf, which will

be dedicated to advancing a nanotechnology controlled-release drug delivery platform.

More